[1]
C. Querfeld, T. Kuzel, J. Guitart, and S. Rosen, “Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma”, Hematol Meeting Rep, vol. 2, no. 13, Jun. 2009.